Biohaven Phase II depression trial for BHV-7000 failed its primary goal, but analysts said the outcome was expected due to trial-design challenges and placebo effects. Wall Street now sees the pivotal Phase III epilepsy study in early 2026 as the key catalyst, while caution remains ahead of seizure data readouts.